The HER2 ELISA Kits Market is developing as demand for advanced oncology diagnostics continues to increase worldwide. The market is expected to grow from around USD 800 million in 2025 to approximately USD 1.2 billion by 2035, with a projected CAGR of 4.4%.

A key trend shaping the market is the increasing emphasis on early cancer detection and personalized treatment. HER2 is an important biomarker associated with certain cancers, particularly breast cancer, and accurate measurement can support treatment-related decision-making.

Advances in ELISA technology are creating additional opportunities. More sensitive and specific assays, automation, multiplex testing, and improved laboratory workflows can help laboratories process samples efficiently. The growing preference for quantitative testing is also encouraging demand for kits capable of providing precise measurements.

The market includes ready-to-use kits, concentrated kits, and multiplex kits. Ready-to-use products offer convenience, while multiplex solutions can support simultaneous detection of multiple targets. Colorimetric, fluorescent, and chemiluminescent detection methods provide laboratories with different testing options.

Hospitals are expected to remain major end users, followed by diagnostic laboratories and research institutions. North America currently represents a strong regional market, while Asia-Pacific offers considerable expansion opportunities.

Increasing cancer research funding, technological development, and rising awareness of targeted therapies are expected to support the long-term growth of the HER2 ELISA kits industry.